Therapeutic Asset Ratings
615 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Fluzoparib
Neoadjuvant Therapy
Fudan University
P3
B
(59)
Osimertinib
Metastatic Malignant Neoplasm In The Brain
Fudan University
P3
B
(59)
Rivoceranib
Neoadjuvant Therapy
Fudan University
P3
B
(59)
Shr-A1811
Triple-Negative Breast Carcinoma
Fudan University
P3
B
(59)
Sorafenib
Breast Cancer
Fudan University
P3
B
(59)
CIS-DIAMMINEDICHLOROPLATINUM II
Rhabdomyosarcoma
Fudan University
P2
B
(59)
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
Breast Cancer
Fudan University
P4
B
(58)
FALLYPRIDE
Breast Cancer
Fudan University
P4
B
(58)
Huaier Granule
Breast Cancer
Fudan University
P4
B
(58)
Huaier Granule
Colorectal Cancer
Fudan University
P4
B
(58)
METHOTREXATE
Her2-Receptor Negative Breast Cancer
Fudan University
P4
B
(58)
CIS-DIAMMINEDICHLOROPLATINUM II
Metastatic Malignant Neoplasm In The Brain
Fudan University
P3
B
(58)
VEMURAFENIB
Metastatic Malignant Neoplasm In The Colon
Fudan University
P3
B
(58)
CIS-DIAMMINEDICHLOROPLATINUM II
Testicular Cancer
Fudan University
P2
B
(58)
Fruquintinib
Colorectal Carcinoma
Fudan University
P2
B
(58)
LENVATINIB
Pancreatic Ductal Adenocarcinoma
Fudan University
P2
B
(58)
Mitoxantrone
Hepatocellular Carcinoma
Fudan University
P2
B
(58)
Pyrotinib
Advanced Colorectal Carcinoma
Fudan University
P2
B
(58)
rc48-adc
Advanced Colorectal Carcinoma
Fudan University
P2
B
(58)
Ddctx
Triple-Negative Breast Carcinoma
Fudan University
P3
B
(57)
Ddepirubicin
Triple-Negative Breast Carcinoma
Fudan University
P3
B
(57)
Docetaxel
Breast Tumor Luminal A Or B
Fudan University
P3
B
(57)
Everolimus
Mutation
Fudan University
P3
B
(57)
Lornoxicam
Triple-Negative Breast Carcinoma
Fudan University
P3
B
(57)
Neratinib
HER2 Positive Breast Carcinoma
Fudan University
P3
B
(57)
Showing 126 to 150 of 615 assets
Previous
Page 6 of 25
Next